#long-acting injectables

Some People With HIV Still Experience Treatment Challenges

Injectable cabotegravir and rilpivirine are approved for people with viral suppression who would prefer monthly injections to daily pills.

I just attended my first CROI (Conference on Retroviruses and Opportunistic Infections). It was also my first virtual conference...

The week of March 6 – March 10, 2021 I had the privilege of attending the Conference on Retroviruses and Opportunistic Infections (CROI).

Long-acting antiretrovirals were the big news at CROI this year; now two of the most promising are joining forces.

A study finds that long-acting cabotegravir is an effective PrEP option for women.

Cabotegravir injections and daily Truvada are both highly effective, but some people may find it easier to use the long-acting regimen.

Injectable cabotegravir and rilpivirine are approved for people with viral suppression who would prefer monthly injections to daily pills.

Whether for treatment or prevention, women’s interest in injectable antiretrovirals varied based on their relationship with injection.

A clinical trial found that switching HIV meds to long-acting Cabenuva may not require oral lead-in.

COVID-19, HIV vaccines, cure news and long-acting injectables stood out among the top HIV treatment stories of the year.

The European Medicines Agency gave the green light to injectable cabotegravir and rilpivirine for HIV treatment.

A new long-acting injectables HIV drug shows promise in monkey study.

A study analyzed how well people with HIV and their health care providers can navigate the experimental long-acting injectable Cabenuva.

Long-acting injectable cabotegravir for HIV prevention could hit the market for men and women in early 2022.